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Due to extensive research, more and more is known about risk factors and 
subsequent preventive actions in pregnancy. Yet in spite of this increasing 
knowledge many risks are still unclear. Epidemiologic research provides a 
substantial contribution to healthy pregnancies. To be able to appoint negative or 
protective effects of health and lifestyle factors around pregnancy on the future 
health of the child, epidemiologic researchers ideally need complete and valid 
information about the widest possible range of pregnancy characteristics and 
detailed information on the outcome under investigation. These data can be 
obtained in various ways, either retro- or prospectively. Although retrospective 
data are often easier to obtain, prospective data collection directly from pregnant 
women has several other advantages. Traditionally data are collected by a pen-
and-paper survey or by interview either face-to-face or by telephone. But ever 
since the Internet is emerging, researchers have been investigating its possibilities 
as a tool for data collection. To explore the possibilities of collecting information on 
medication use and other potential risk factors directly from pregnant women via 
the Internet, the PROTECT pregnancy study was set up. 
This thesis aims to investigate the different methods of data collection of risk 
factors in pregnancy. In addition, several observational epidemiologic study designs 
were used to assess associations between risk factors and negative birth outcomes. 
The benefits and drawbacks of the use of the Internet for data collection are 
elaborated, along with those of more traditional methods. Direct data collection 
from the pregnant women themselves is compared to indirect data collection from 
existing databases like the IADB.nl pregnancy database, a pharmacy prescription 
database and EUROCAT NNL, a birth defect registry. This thesis focuses on the 
collection of data on medication use during pregnancy and the investigation of 
relations between the use of particular medications during pregnancy and several 
negative effects for the child. Besides evaluating folic acid as a supplement to 
promote the health of the baby we will also focus on asthma and the use of 
asthma medication during pregnancy as potential risk factors for the baby’s health. 
Following the General Introduction, Section 2 covers direct data collection via pen-
and-paper questionnaires. After the establishment of the preventive effect of folic 
acid on the development of neural tube defects, folic acid supplementation before 
and during pregnancy was recommended in the Netherlands since the nineties of 
the 20th century. Since 1995, regular surveys have been carried out among 
pregnant women in the Northern Netherlands to evaluate the effects of the 








Chapter 2.1 describes the results of the 2009 survey into knowledge and use of 
folic acid. Of all respondents, 51.6% reported to have used an adequate dose of at 
least 400 mcg folic acid during the entire recommended period from 4 weeks 
before until 8 weeks after conception. Planned pregnancy, smoking, folic acid use 
during a former pregnancy and the number of previous children, were predicting 
factors for the recommended use of folic acid. The knowledge about folic acid 
declined and the use during the recommended period did not improve since the 
survey of 2005. Based on this survey we conclude that there is still room for 
improvement with respect to knowledge and actual use of folic acid before 
pregnancy, especially with younger, low-educated women. Counselling should 
include family planning and use of contraceptives. In chapter 2.2 we show the 
results of the survey conducted in 2014, especially focusing on the development in 
knowledge and use of folic acid throughout the years. The absence of an incentive 
for the participating practices and the involvement in other studies affected the 
response rate of the 2014 survey substantially compared to the earlier ones (49.7% 
against 75-94%). With a recommended folic acid use of 56.2% in 2014, folic acid 
supplementation around pregnancy has stabilized during the last decade in the 
Netherlands. Since almost 90% of participating women knew about folic acid 
before they got pregnant already, the question remains how and whether 
recommended folic acid supplementation can be increased substantially. 
Reimbursing preconception consultation by midwives or other health care workers 
might contribute to a better uptake of the folic acid supplementation advice. 
In chapter 2.3 we evaluate the representativeness of The Healthy Pregnant data 
set, a Dutch non-malformed control group collected from two midwife practices to 
see if it is useful as a control-group for EUROCAT NNL. The Healthy Pregnant data 
set was not representative of the general pregnant population in the northern part 
of the Netherlands. Women from both low and high education levels were 
overrepresented. Mothers were more likely to have a body mass index  > 25 kg/m2 
or to smoke but were less likely to consume alcohol. Specifically, the exposure to 
(chronic) drugs was underestimated, possibly because women with a chronic 
condition are referred to second-line care on the basis of medical indication. In the 
absence of a representative non-malformed control group, a genetic disorder 
control group should be considered as an appropriate solution. When conducting a 
control group for epidemiological research to evaluate the effects of medication 
use in pregnancy on the development of birth defects, it is more important that 
exposures to drugs are representative than the fact that the control group consists 
of non-malformed pregnancy outcomes, especially considering that malformed 
controls (chromosomals) can reduce recall bias. 
  





In section three of the thesis indirect data collection is elaborated and the studies 
in this section all use the IADB.nl or EUROCAT NNL database. In chapter 3.1, we use 
the IADB.nl pregnancy database to describe changes in prescriptions for asthma 
medications to patients around their pregnancy. We collected data over a study 
period of 1 year before pregnancy until 6 months after birth, and analysed data 
from pregnant women who received at least 1 prescription for asthma medication 
during the study period (n=2072), identifying all prescriptions of asthma 
medication and oral corticosteroids. The study showed a significant increase in 
prescriptions for asthma medications among pregnant women in the period from 
2004 to 2009, compared to the period before 2004, especially for the relatively 
new long-acting bronchodilators and combination preparations. Despite their 
understanding of the importance of adequate asthma-control, many women stop 
their controller therapy when they become pregnant. We observed a significant 
decrease in prescription of asthma medications during the first trimester of 
pregnancy in the period from 2004 until 2009, especially for long-acting 
bronchodilators, usually prescribed for patients with more severe asthma. 
Discontinuation could lead to severe symptoms of respiratory distress, along with 
risk of maternal and neonatal complications. There is room for improvement in 
treating asthma in pregnant women, which could lead to better health and care for 
mothers and children. 
As stated before, folic acid supplementation of at least 400 mcg a day, before and 
in the beginning of pregnancy is recommended to reduce the risk of having a child 
with a neural tube defect. Women using folic acid antagonists, like antiepileptic 
drugs, women at risk for developing anaemia and women who have developed 
anaemia may receive a prescription for high dose folic acid (5mg). Chapter 3.2 
describes the results of our study investigating delivery of high dose folic acid 
during pregnancy and the association with the use of asthma medication in the 
offspring, using the IADB.nl pregnancy database, since folic acid supplementation 
taken during pregnancy has been associated with an increased risk for childhood 
asthma. Delivery of asthma medication in children exposed in utero to high dose 
folic acid was compared to children who were not exposed to this high dose. High 
dose folic acid was dispensed in almost 3% of pregnancies, increasing with the 
course of pregnancy, especially with multiple pregnancies. The risk for asthma 
medication after exposure to maternal high dose folic acid during pregnancy 
increased up to 26% for the recurrent prescription of inhalation corticosteroids. 
Timing of folic acid use during pregnancy did not seem to have a significant effect 
on the associations studied. Additional research based on other data sources is 
recommended to confirm the association found. 
After consumption, folic acid is metabolized by dihydrofolate reductase (DHFR) to 
its bioactive form 5-methyltetrahydrofolate (5-MTHF) that acts as a methyl-
acceptor or -donor in biochemical reactions in the fetus, that are important for 








In chapter 3.3 we describe the results of case-control study investigating any 
increased risk on the development of folic acid sensitive birth defects after first 
trimester exposure to folic acid antagonists using the EUROCAT NNL database and 
the effect of concomitant intake of folic acid supplementation. We did not find an 
increased risk for folic acid sensitive birth defects after first trimester use of a folic 
acid antagonist. Investigating the several subgroups of births defects, an Odds 
Ratio >1 was only found for first trimester use of antiepileptic drugs and the 
occurrence of neural tube defects. We did not find a significant protective effect of 
the use of folic acid supplementation when using a folic acid antagonist during the 
first trimester of pregnancy. For risk assessment studies looking at birth defects, 
and especially birth defects that are rare, acquiring an adequate number of cases, 
is a challenge. For many of the associations studied, the numbers were too low to 
calculate Odds Ratios or to draw conclusions. 
In Chapter 3.4, the IADB.nl pregnancy database and EUROCAT NNL are combined 
to see whether a comparison of drug use rates from the birth defect registry 
EUROCAT NNL (cases) with prescription rates from the population-based 
prescription database IADB.nl, (population), could be used to detect signals of 
teratogenic risk of drugs. We show that a case-population study is a suitable 
method for detecting signals of possible teratogenicity, provided that the 
teratogenic effects and drugs under study are as specific as possible and the drugs 
are widely used.  
Section four describes data collection in pregnancy using web-based 
questionnaires. Chapter 4.1 shows the results of a systematic review investigating 
the use of web-based surveys examining a pregnancy-related topic. The literature 
search resulted in a sample of 37 eligible publications published from 2000 to 2013 
collecting data for epidemiologic research from women who wanted to get 
pregnant, were pregnant or had been pregnant, by using an online questionnaire. 
As Internet use is increasing over time so were the number of publications we 
found per year. For the assessment of associations between exposure during 
pregnancy and pregnancy outcome, data collected should be complete and valid. 
We found no evidence of self-reported web-based data being more prone to 
incompleteness or non-validity than the same data collected via traditional 
methods like pen-and-paper, telephone surveys or interviews.  When data could be 
compared to results from recent literature using other methods of data collection, 
results largely corresponded but completeness and validity are hard to judge 
because often no gold standard or other data sources are available, especially 
when perception is investigated. Due to possible selectivity of the sample, data 
obtained via open recruitment on the Internet is less suitable to calculate 
prevalences, but literature shows that web-responders do compare to responders 
by paper on most demographic variables when the same recruitment method is 
used.  
  





To evaluate the potential contribution of collecting information on medication use 
and other potential risk factors directly from pregnant women via the Internet for 
research purposes, the PROTECT pregnancy study was started. In this non-
interventional, prospective study ran in 4 European countries, pregnant women 
were asked to provide information about their health, lifestyle factors and 
medication use in their current pregnancy via a web-based questionnaire. In 
chapter 4.2 we investigate whether a database like the PROTECT pregnancy study 
can be used to explore potential relationships between lifestyle factors and birth 
outcomes. Lifestyle factors and birth outcomes reported by the women 
participating in PROTECT are compared to data from the general pregnant 
population of the participating countries or found in literature. The  PROTECT 
pregnancy study recruited a selected population and characteristics investigated 
varied highly between the participating countries. Women participating in 
PROTECT were at average older, more highly educated and more health-focused. 
PROTECT participants also planned their pregnancy more often and generally took 
more folic acid supplements and multivitamins. Medication for different chronic 
conditions were also used more often, except for diabetes. The composition of the 
study sample will be determined by Internet access of the target population but 
Internet access hardly is a restricting factor in Western countries nowadays. The 
lack of population data as a gold standard and the diversity of data found in 
literature shows the difficulty of establishing the validity of lifestyle data reported. 
We found no conclusive evidence however to undervalue the validity and 
completeness of self-reported Internet-derived data compared to data obtained 
via traditional survey methods or derived from health care workers or medical 
databases, except for data on birth defects. 
In chapter 4.3 a web-based survey is used to investigate the perceptions of 
pregnant women about the risks of their asthma and asthma medication for their 
offspring. Pregnant women with asthma were asked to provide information about 
asthma control and management before and during pregnancy and about the 
information they got on risk of asthma and asthma medication for the unborn 
child. In spite of guidelines advising the opposite, our study shows that still many 
women are advised by their physician to stop or change their current asthma 
medication when planning a pregnancy or after pregnancy is identified, leading to 
an increase in asthma symptoms for more than half of them. In line with chapter 
3.1, generally relatively new medications containing a long-acting bronchodilator 
for maintenance of more severe asthma were stopped or changed to the older 
plain inhalation corticosteroids with substantial risk of the asthma getting less well 
controlled with consequent risks for the infant. Many women have their worries 
about possible risks of their asthma and their asthma medications and perceive a 
lack of support and guidance. Almost one third of the respondents indicated that 








In the field of asthma management during pregnancy there is still a lot to gain. 
Despite sufficient knowledge, latest guidelines are often not being followed. 
Healthcare providers need to be educated about the practical implementation of 
their knowledge about the importance of adequate asthma control in pregnancy.  
Finally, we conclude that several factors have their influence on recruitment of 
participants for epidemiologic research and on the size and composition of the 
survey sample, and the different methods of data collection all have their 
opportunities and drawbacks, including new methodology like collecting data via 
the Internet. 
